latest-news-headlines Market Intelligence /marketintelligence/en/news-insights/latest-news-headlines/license-to-pill-biotech-and-pharma-deals-from-july-11-july-24-59605836 content
Log in to other products

Login to Market Intelligence Platform


Looking for more?

Contact Us

Request a Demo

You're one step closer to unlocking our suite of comprehensive and robust tools.

Fill out the form so we can connect you to the right person.

If your company has a current subscription with S&P Global Market Intelligence, you can register as a new user for access to the platform(s) covered by your license at Market Intelligence platform or S&P Capital IQ.

  • First Name*
  • Last Name*
  • Business Email *
  • Phone *
  • Company Name *
  • City *
  • We generated a verification code for you

  • Enter verification Code here*

* Required

Thank you for your interest in S&P Global Market Intelligence! We noticed you've identified yourself as a student. Through existing partnerships with academic institutions around the globe, it's likely you already have access to our resources. Please contact your professors, library, or administrative staff to receive your student login.

At this time we are unable to offer free trials or product demonstrations directly to students. If you discover that our solutions are not available to you, we encourage you to advocate at your university for a best-in-class learning experience that will help you long after you've completed your degree. We apologize for any inconvenience this may cause.

In This List

License to Pill: Biotech and pharma deals from July 11-July 24

COVID-19 Pandemic Likely To Cause US Telemedicine Boom

Gauging Supply Chain Risk In Volatile Times

S&P Global Market Intelligence

Cannabis: Hashing Out a Budding Industry


IFRS 9 Impairment How It Impacts Your Corporation And How We Can Help

License to Pill: Biotech and pharma deals from July 11-July 24

Deal-making activity picked up pace for the two weeks ended July 24, with Roche Holding AG and GlaxoSmithKline PLC among those entering into licensing deals, according to data compiled by S&P Global Market Intelligence.

Collaborations during the two-week span covered treatments for a number of diseases including cancer, heart disease, hepatitis B and nervous system disorders.

Basel, Switzerland-based pharmaceutical giant Roche signed the largest agreement by up-front payment with Blueprint Medicines Corp. for rights to jointly develop and commercialize cancer drug pralsetinib for treating RET-altered non-small cell lung cancer, medullary thyroid cancer and other types of thyroid cancer, as well as other solid tumors.

Roche will pay $675 million in cash up front for rights to the drug outside the U.S. — excluding China, Hong Kong, Macau and Taiwan. Blueprint could receive up to $927 million in milestone payments and royalties in addition to a $100 million equity investment from the Swiss drugmaker.

Roche also signed another pact with Boston-based private biotechnology company Jnana Therapeutics Inc. for the license to discover small molecule drugs for treating immune-mediated and neurological diseases.

The biotech company will get a cash payment of $40 million up front and is eligible to receive over $1 billion from the Swiss company in research funding, milestone payments and royalties.

Another notable agreement during the two-week period was between Glaxo SmithKline and Germany's CureVac AG to collaborate on up to five mRNA-based vaccines and monoclonal antibodies for infectious diseases.

Private biotechnology company CureVac will receive £104 million cash up front in addition to a £130 million investment by the British pharmaceutical giant and a one-time reimbursable payment of £26 million for manufacturing capacity reservation.

CureVac also filed for an IPO to list its shares on the Nasdaq Global Market.

Meanwhile, Merck KGaA extended its collaboration with F-Star Biotechnology Ltd. and exercised an early option to license a preclinical program. The companies have been working together since 2017 to develop five bispecific immuno-oncology antibodies.

This is the second preclinical program that Merck has licensed from the Cambridge, U.K.-based biotechnology company under the collaboration.

SNL Image